Physician profile
Sudha Niraula
NPI 1962632869
$935.89
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $344 · 2021: $181.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $256.41 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $146.17 | 2019-2021 | |
| Pfizer INC. | $123.11 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.04 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $58.02 | 2019-2020 | |
| Vifor Pharma, INC. | $46.06 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $44.52 | 2019 | |
| Paratek Pharmaceuticals, INC. | $40.71 | 2020-2021 | |
| Allergan, INC. | $36.01 | 2019 | |
| Mylan Specialty L.P. | $22.06 | 2019 | |
| Shire North American Group INC | $21.41 | 2019 | |
| Abbvie INC. | $15.12 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.62 | 2019 | |
| Portola Pharmaceuticals, LLC | $14.01 | 2019 | |
| Merck Sharp & Dohme LLC | $13.62 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudha Niraula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.